SPOTLIGHT -
EP. 1: Surgery in Early-Stage Ovarian Cancer
EP. 2: Chemotherapy in Early-Stage Ovarian Cancer
EP. 3: Molecular Testing in Ovarian Cancer
EP. 4: Surgical Controversies in Advanced Ovarian Cancer
EP. 5: Neoadjuvant Therapy in Advanced Ovarian Cancer
EP. 6: Targeting VEGF in Advanced Ovarian Cancer
EP. 7: Advanced Ovarian Cancer: Emerging Therapies
EP. 8: Using Novel Therapies in Advanced Ovarian Cancer
EP. 9: The GOG-0213 Trial in Recurrent Ovarian Cancer
EP. 10: A New Standard of Care in Recurrent Ovarian Cancer?
EP. 11: PARP Maintenance Therapy in Recurrent Ovarian Cancer
EP. 12: Using Maintenance Therapy in Recurrent Ovarian Cancer
EP. 13: Recurrent Ovarian Cancer: PARP Inhibitors Compared
EP. 14: Ongoing PARP Trials in Recurrent Ovarian Cancer
EP. 15: PARP Combination Therapies in Ovarian Cancer
EP. 16: Novel Treatment Strategies in Recurrent Ovarian Cancer
EP. 17: Improvements in Advanced Ovarian Cancer
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma